Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Unit Collaborates With Persephone Biosciences On Stool Analysis

09/21/2021 | 12:53pm EDT


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
10/26Johnson & Johnson Statement on Texas Opioid Settlement Agreement
PU
10/26Protagonist Therapeutics Gets $7.5 Million Milestone Payment from Johnson & Johnson's J..
MT
10/26New Analyses Suggest Favorable Results for STELARA (ustekinumab) When Used as a First-L..
AQ
10/25Pfizer, Moderna and J&J Booster Shots Now Available at Walmart and Sam's Club Pharmacie..
AQ
10/25MODERNA : Walgreens Now Offering Moderna and Johnson & Johnson COVID-19 Vaccine Booster Sh..
AQ
10/25JOHNSON & JOHNSON : New Analyses Suggest Favorable Results for STELARA« (ustekinumab) When..
PU
10/25The Janssen Pharmaceutical Companies of Johnson & Johnson announces New Analyses Sugges..
CI
10/22Walgreens Starts Offering Moderna, Johnson & Johnson COVID-19 Booster Shots
MT
10/22CDC approves Moderna, J&J COVID-19 boosters, mixing and matching doses
AQ
10/22MODERNA : CDC Endorses Booster Doses of Moderna, J&N COVID-19 Vaccines
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 279 M - -
Net income 2021 22 540 M - -
Net cash 2021 924 M - -
P/E ratio 2021 20,0x
Yield 2021 2,52%
Capitalization 436 B 436 B -
EV / Sales 2021 4,62x
EV / Sales 2022 4,33x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 165,75 $
Average target price 185,94 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231
MERCK & CO., INC.0.55%208 206